Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Autor: | Ray, Kausik K *, Troquay, Roel P T, Visseren, Frank L J, Leiter, Lawrence A, Scott Wright, R, Vikarunnessa, Sheikh, Talloczy, Zsolt, Zang, Xiao, Maheux, Pierre, Lesogor, Anastasia, Landmesser, Ulf |
---|---|
Zdroj: | In The Lancet Diabetes & Endocrinology February 2023 11(2):109-119 |
Databáze: | ScienceDirect |
Externí odkaz: |